2023-04-24 11:58:12 ET
- Citius Pharmaceuticals ( NASDAQ: CTXR ) is down 8% in late Monday moring trading despite reporting that it is near completion of a phase 3 trial for its Mino-Lok system.
- Mino-Lok is an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. It contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol to eliminate bacteria in central venous catheters.
- The company said that ~85 of the 92 events necessary to finish the trial are completed . The trial has 190 patients enrolled.
- Read why Investing Groups Leader Bret Jensen considers Citius ( CTXR ) a hold.
For further details see:
Citius Pharma down 8% despite close to end of late-stage Mino-Lok trial